Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

Benha University

Status and phase

Completed

Phase 2

Conditions

Human Papilloma Virus (HPV)

Cutaneous Warts

Treatments

Drug: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Drug: Intralesional polidocanol 2%

Study type

Interventional

Funder types

Other

Identifiers

NCT07307131

intralesional treatment warts

Details and patient eligibility

About

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Full description

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

Enrollment

64 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients over 18 years of age with single or multiple cutaneous warts.

Exclusion criteria

History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.